Tuesday, October 9, 2012
Making the best medicines possible to treat the greatest number of patients
Tuesday, October 9th: Making the best medicines possible to treat the greatest number of patients, 4 pm. Register here: http://bit.ly/UCKc0K
Ho Sung Cho will describe the common boons and banes of biotech entrepreneurship, especially as it applies to developing highly disruptive technologies in an increasingly risk-averse climate. Specific topics include managing expectations of investors, benefits and trade-offs of corporate partnerships, why routes to acquisitions and IPOs are not so straightforward, and why there will never be another Genentech or Amgen.
Ho Sung Cho, Ph.D. is currently Chief Technology Officer at Ambrx, a biopharmaceutical company focused on the development of protein-chemical conjugates spun out of Peter Shultz's lab at Scripps. Prior to joining Ambrx, Dr. Cho served as the Associate Director of Protein Chemistry at Xencor where he modernized the department's capabilities in high throughput protein expression and purification, and developed a strategy for protein PEGylation applied to the first clinical candidate. Prior to Xencor, Dr. Cho was at Exelixis where he was the Team Leader responsible for all internal protein needs for HTP screening and structural biology. Prior to joining industry, Dr. Cho was a staff scientist at Lawrence Berkeley National Labs where he worked on the structural genomics project, applying NMR spectroscopy and X-ray crystallography to determine structures of proteins at atomic resolution. In addition to his interest in proteins, Dr. Cho has a strong affinity for synthetic chemistry as he began his scientific career as a medicinal chemist in the Oncology Department at Burroughs Wellcome, RTP.